Research Analyzes Benefits of GLP-1 Medications Amid Affordability Challenges
CVS Health has unveiled new findings based on actual healthcare utilization data that scrutinize the economic impact of GLP-1 medications, which are increasingly used among various patient demographics. This analysis seeks to determine if the health benefits associated with these medications can justify their costs for employers and healthcare plans.
According to the research, which utilises Aetna claims data from fully insured members, patients utilizing GLP-1 medications report improved health outcomes, reduced hospital admissions, and decreased overall medical expenditures when compared with similar patients who do not use these medications. However, the primary concern remains: at present pricing levels, these savings do not completely cancel out the expenses incurred from pharmacy costs.
Dr. Amy Compton-Phillips, a lead researcher at CVS Health, stated, "GLP-1 medications are incredibly effective, and patients invariably experience notable health improvements. The core issue we are addressing is how to make these benefits widely affordable. This involves ensuring that the right patients receive treatment, maintaining adherence to therapy, and, crucially, lowering medication prices to extend access to these life-changing drugs."
The study monitored Aetna members prescribed GLP-1s between 2023 and 2025, with up to three years of follow-up data. Researchers meticulously matched users with non-users based on criteria such as age, existing health issues, previous medical utilization, as well as overall spending on medical and pharmaceutical services.
Simulation results reveal that a manageable net price of approximately $350 per month over a three-year period could level the playing field between pharmacy spending and the observed healthcare savings. However, this break-even price fluctuates based on variables including the patient's initial health risks, treatment duration, and adherence levels.
In addition, the research underscored the importance of treatment continuity by comparing individuals starting on GLP-1 therapy with those whose prescriptions covered 80% or more of the days over the study period—a benchmark for assessing medication adherence.
To enhance the utility of GLP-1 medications, the researchers identified three critical steps:
1. Prioritize treating those patients who stand to gain the most, informed by clinical evidence and particular individual needs.
2. Support patients in adhering to their treatment regimens long enough to experience tangible health benefits.
3. Reduce the cost of these medications to facilitate broader access and maintain overall healthcare affordability.
As the application of GLP-1 therapies broadens—initially designed for managing type 2 diabetes but now extending to conditions like obesity and various cardiovascular, liver, and kidney diseases—the urgency surrounding cost-effectiveness becomes more pronounced. The findings suggest that an astonishing 137 million adults in the U.S. qualify for semaglutide across several medical indications, with many meeting criteria for multiple conditions.
While this analysis emphasizes the importance of achieving a financial break-even point, it does not advocate that this metric should be the sole determinant of the value of these medications. Instead, it highlights why pricing is paramount for employers and health plans striving to increase accessibility to this effective category of drugs without imposing excessive financial burdens on the healthcare infrastructure.
Dr. Compton-Phillips is set to discuss these insights further during an upcoming presentation at the HLTH industry conference in Las Vegas. For those interested in a deeper dive into the research, CVS Health has released a comprehensive white paper titled "GLP-1s: Good Drugs, High Prices," which can be accessed freely at their official website.
According to the research, which utilises Aetna claims data from fully insured members, patients utilizing GLP-1 medications report improved health outcomes, reduced hospital admissions, and decreased overall medical expenditures when compared with similar patients who do not use these medications. However, the primary concern remains: at present pricing levels, these savings do not completely cancel out the expenses incurred from pharmacy costs.
Dr. Amy Compton-Phillips, a lead researcher at CVS Health, stated, "GLP-1 medications are incredibly effective, and patients invariably experience notable health improvements. The core issue we are addressing is how to make these benefits widely affordable. This involves ensuring that the right patients receive treatment, maintaining adherence to therapy, and, crucially, lowering medication prices to extend access to these life-changing drugs."
The study monitored Aetna members prescribed GLP-1s between 2023 and 2025, with up to three years of follow-up data. Researchers meticulously matched users with non-users based on criteria such as age, existing health issues, previous medical utilization, as well as overall spending on medical and pharmaceutical services.
Simulation results reveal that a manageable net price of approximately $350 per month over a three-year period could level the playing field between pharmacy spending and the observed healthcare savings. However, this break-even price fluctuates based on variables including the patient's initial health risks, treatment duration, and adherence levels.
In addition, the research underscored the importance of treatment continuity by comparing individuals starting on GLP-1 therapy with those whose prescriptions covered 80% or more of the days over the study period—a benchmark for assessing medication adherence.
To enhance the utility of GLP-1 medications, the researchers identified three critical steps:
1. Prioritize treating those patients who stand to gain the most, informed by clinical evidence and particular individual needs.
2. Support patients in adhering to their treatment regimens long enough to experience tangible health benefits.
3. Reduce the cost of these medications to facilitate broader access and maintain overall healthcare affordability.
As the application of GLP-1 therapies broadens—initially designed for managing type 2 diabetes but now extending to conditions like obesity and various cardiovascular, liver, and kidney diseases—the urgency surrounding cost-effectiveness becomes more pronounced. The findings suggest that an astonishing 137 million adults in the U.S. qualify for semaglutide across several medical indications, with many meeting criteria for multiple conditions.
While this analysis emphasizes the importance of achieving a financial break-even point, it does not advocate that this metric should be the sole determinant of the value of these medications. Instead, it highlights why pricing is paramount for employers and health plans striving to increase accessibility to this effective category of drugs without imposing excessive financial burdens on the healthcare infrastructure.
Dr. Compton-Phillips is set to discuss these insights further during an upcoming presentation at the HLTH industry conference in Las Vegas. For those interested in a deeper dive into the research, CVS Health has released a comprehensive white paper titled "GLP-1s: Good Drugs, High Prices," which can be accessed freely at their official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.